



HAL
open science

Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial

João Pedro Ferreira, John G F Cleland, Nicolas Girerd, Pierpaolo Pellicori, Mark R Hazebroek, Job Verdonschot, Timothy J Collier, Johannes Petutschnigg, Andrew L Clark, Jan A Staessen, et al.

► To cite this version:

João Pedro Ferreira, John G F Cleland, Nicolas Girerd, Pierpaolo Pellicori, Mark R Hazebroek, et al.. Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial. *Clinical Research in Cardiology*, 2023, 112 (2), pp.330-332. 10.1007/s00392-022-02116-w . hal-03830091

HAL Id: hal-03830091

<https://hal.univ-lorraine.fr/hal-03830091v1>

Submitted on 26 Oct 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial

João Pedro Ferreira^{1,2}; John G. F. Cleland³; Nicolas Girerd²; Pierpaolo Pellicori³; Mark R. Hazebroek⁴; Job Verdonschot⁵; Timothy J. Collier⁶; Johannes Petutschnigg⁷; Andrew L. Clark⁸; Jan A. Staessen⁹; Stephane Heymans⁴; Faiez Zannad²; Patrick Rossignol²

¹ UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.

² INSERM, Centre d'Investigations Cliniques - Plurithématique 14-33, Université de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

³ Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, United Kingdom.

⁴ Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands.

⁵ Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.

⁶ London School of Hygiene and Tropical Medicine, London, UK.

⁷ Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin and German Centre for Cardiovascular Research (DZHK), Berlin, Germany.

⁸ Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, UK.

⁹ Research Institute Alliance for the Promotion of Preventive Medicine, Mechelen,
Belgium.

Contact to:

Dr João Pedro Ferreira

CIM - Centro de Investigação Médica

Faculdade de Medicina UP - Piso 6 - DCF

Rua Plácido da Costa, s/n

4200-450 Porto, Portugal

Tel : +351 22 551 3600

Mail: jpferreira@med.up.pt

Summary

Spironolactone reduces estimated glomerular filtration rate (eGFR) soon after initiating treatment, but mineralocorticoid receptor antagonists (MRA) may prevent longer-term decline in eGFR. We studied the effect of spironolactone (compared to usual care) on eGFR changes and its biomarker correlations in 527 people at risk of developing heart failure enrolled in the HOMAGE trial. eGFR was determined at baseline, one and nine months. Compared to usual care, spironolactone reduced eGFR from baseline to month one: -3 (-4 to -2) ml/min/1.73m², $P < 0.001$ (corresponding to a -4% change on average). Spironolactone caused no further reduction in eGFR from month one to month nine: -1 (-3 to 0) ml/min/1.73m², $P = 0.085$. eGFR decrease between baseline and one month was positively correlated with brain natriuretic peptide and kidney injury molecule 1. Thus, spironolactone induces a small, early eGFR decrease without evidence of renal tubular injury, suggesting an early hemodynamic effect.

Key-words: estimated glomerular filtration rate; tubular injury; spironolactone; heart failure risk.

Background

Mineralocorticoid receptor antagonists (MRA) induce hemodynamic changes that reduce estimated glomerular filtration rate (eGFR), which usually occurs early after treatment initiation and then stabilises and is generally of small magnitude, and not associated with a decrease of clinical benefit from MRA therapy.¹⁻³ However, clinicians may withhold or stop spironolactone (and other RAAS inhibitors) when eGFR decreases (even if transient), which may increase the risk of subsequent events.⁴

In the HOMAGE (Heart OMics in AGEing; NCT02556450) trial enrolling patients with risk factors for developing heart failure (HF), spironolactone (compared to usual care) reduced markers of collagen synthesis, blood pressure, natriuretic peptides, and improved cardiac structure and function, while decreasing eGFR by ~5 ml/min/1.73m² from baseline to month 9.⁵

The factors associated with early and late eGFR decrease and respective biomarker correlations have not been studied in this population.

Methods

The HOMAGE clinical trial was a prospective, randomized, open-label, blinded-endpoint (PROBE) study comparing spironolactone vs. usual care in people at increased risk of developing HF. The protocol and design of HOMAGE have been previously described.⁶ In short, the main inclusion criteria were age greater than 60 years, plasma concentrations of natriuretic peptides above the normal range, coronary artery disease or at least two of the following: diabetes mellitus,

hypertension, microalbuminuria, or abnormal ECG. The key exclusion criteria were an eGFR <30 ml/min/1.73 m², serum potassium >5.0 mmol/L, left ventricular ejection fraction $<45\%$, atrial fibrillation, a prior diagnosis of HF, or treatment with loop diuretics. After randomization, eGFR was assessed at one and nine months. Spironolactone was initiated at a dose of 25 mg/day. Doses could be increased up to 50 mg/day or reduced to 25 mg every other day or stopped with or without re-initiation according to serum potassium.^{6,7} Furthermore, spironolactone had to be discontinued if eGFR fell to or below 30ml/min/1.73m². Treatment could be restarted at the investigator's discretion if eGFR rose above 30ml/min/1.73m².

Worsening renal function (WRF) $>20\%$ from baseline was a prespecified secondary outcome.

In this analysis, eGFR was determined using the CKD-EPI 2009 creatinine-based formula. The effect of spironolactone on early and late eGFR changes was assessed by analysis of covariance. Patients' characteristics were compared across tertiles of early and late eGFR changes. Associations between eGFR changes and changes in biomarkers of cardiac stretch (BNP, brain natriuretic peptide), tubular kidney injury (KIM1, kidney injury molecule-1), mineralocorticoid receptor blockade feedback (renin), and systolic blood pressure (SBP) were assessed with linear regression models. Analyses were performed using Stata® version 17.1 (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC).

Results

Spironolactone effect on early and late eGFR changes

A total of 527 participants (265 spironolactone and 262 usual care) were included in the analysis. *Supplementary Table 1*. Compared to usual care, spironolactone decreased eGFR from baseline to month one: -3 (-4 to -2) ml/min/1.73m², P <0.001 (corresponding to a -4% change on average). This effect was similar in patients with baseline eGFR above or below 60 ml/min/1.73m², interactionP =0.63. On the other hand, spironolactone did not decrease eGFR between months one and nine: -1 (-3 to 0) ml/min/1.73m², P =0.085. No significant interaction was found by eGFR above or below 60 ml/min/1.73m² measured at one month, interactionP =0.11. *Figure 1*.

The proportion of patients with eGFR decrease ≥20% from baseline was small and not significantly different between spironolactone and usual care: any timepoint: spironolactone =36 (14.0%) vs. usual care =25 (9.9%), P =0.15; baseline to month one spironolactone =14 (5.5%) vs. usual care =6 (2.4%), P =0.074; month one to month nine, spironolactone =22 (8.9%) vs. usual care =19 (7.6%), P =0.60. The proportion of patients with eGFR drop ≥30% from baseline was also small and not significantly different between spironolactone and usual care: any timepoint: spironolactone =16 (6.2%) vs. usual care =8 (3.2%), P =0.10; baseline to month 1, spironolactone =5 (1.9%) vs. usual care =1 (0.4%), P =0.11; month 1 to month 9, spironolactone =11 (4.5%) vs. usual care =7 (2.8%), P =0.32.

Patient's characteristics across tertiles of eGFR change

Compared to patients in whom eGFR increased from baseline to month one, those in whom eGFR decreased had higher eGFR at baseline and were more often randomized to spironolactone (P <0.01 for both). *Supplementary Tables 2 & 3*.

Association between eGFR and circulating biomarker changes

eGFR decrease from baseline to month one was caused by spironolactone initiation (without differences in the usual care group) and these were negatively correlated (i.e., eGFR decrease/biomarker increase) with renin, and positively correlated (i.e., eGFR decrease/biomarker decrease) with BNP, KIM-1, and SBP ($P < 0.01$ for all). No biomarker predicted the occurrence of WRF $> 20\%$.

Conclusion

This analysis shows that spironolactone exerted a small decrease in eGFR from baseline to month one, without a significant difference thereafter compared to a control group, suggesting that the eGFR decrease associated with spironolactone is caused by early hemodynamic changes without renal injury; findings that are further supported by a positive correlation with BNP, KIM-1 and SBP decrease.

Graphical abstract.

These findings expand those from RALES, EMPHASIS-HF and TOPCAT in patients with chronic HF with reduced or preserved ejection fraction, where steroid-based MRAs induced a mild eGFR decrease (from -2 to -4 ml/min/1.73m²) that was apparent within weeks of treatment initiation, but thereafter participants assigned to MRA experienced eGFR trajectories similar to those observed with placebo in the following years. Together these data suggest that steroid-based MRAs cause an early eGFR decrease but do not accelerate long-term, age-related decline in renal function in patients at risk for or with chronic HF.

In HOMAGE the early eGFR decrease was negatively correlated with the increase in plasma renin concentration, which occurs as a feedback mechanism to the blockade of the mineralocorticoid receptor by spironolactone.⁸ The positive

correlation between eGFR decrease and BNP, KIM-1, and SBP supports the hypothesis that the early eGFR decrease after initiating spironolactone is hemodynamic in origin rather than reflecting structural renal damage or tubular injury.^{9,10}

In summary, among patients at risk of developing heart failure enrolled in HOMAGE, spironolactone induced an early and mild eGFR decrease due to hemodynamic changes in the kidney, without evidence of tubular injury. After 1 month, changes in eGFR were similar between spironolactone and usual care.

Ethics approval and consent to participate

The study was approved by all relevant ethics committees and regulatory bodies. All participants provided written informed consent prior to study specific procedures.

Consent for publication

There is no data of individual persons included in the manuscript.

Competing interests


The authors have no relevant conflicts of interest to disclose regarding the content of this manuscript.

References

1. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *Circ Heart Fail*. 2014;7:51-58. doi: 10.1161/circheartfailure.113.000792
2. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). *J Am Coll Cardiol*. 2012;60:2082-2089. doi: 10.1016/j.jacc.2012.07.048
3. Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, et al. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. *J Am Coll Cardiol*. 2021;77:1211-1221. doi: 10.1016/j.jacc.2020.12.057
4. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. *Lancet*. 2019;393:1034-1044. doi: 10.1016/s0140-6736(18)31808-7
5. Cleland JGF, Ferreira JP, Mariotoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. *Eur Heart J*. 2020. doi: 10.1093/eurheartj/ehaa758
6. Pellicori P, Ferreira JP, Mariotoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, et al. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. *Eur J Heart Fail*. 2020. doi: 10.1002/ejhf.1716
7. Monzo L, Ferreira JP, Cleland JGF, Pellicori P, Mariotoni B, Hazebroek MR, Collier TJ, Cuthbert JJ, Pieske B, Petutschnigg J, et al. Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial. *ESC Heart Fail*. 2022. doi: 10.1002/ehf2.14086
8. Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, et al. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. *JACC Heart Fail*. 2021. doi: 10.1016/j.jchf.2020.11.010
9. Ferreira JP, Rossignol P, Bakris G, Mehta C, White WB, Zannad F. Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. *Am J Nephrol*. 2021;52:969-976. doi: 10.1159/000519436
10. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, Felker GM, Hernandez AF, O'Connor CM, Sabbisetti VS, et al. Worsening

Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. *Circulation*. 2018;137:2016-2028. doi: 10.1161/circulationaha.117.030112

Figure 1. eGFR change from baseline to month 1 and month 1 to month 9 in spironolactone and usual care (“control”) groups




Caption: Compared to usual care, spironolactone decreased eGFR from baseline to month 1 by -3 (-4 to -2) ml/min/1.73m², P <0.001; spironolactone did not significantly change eGFR from month 1 to month 9: -1 (-3 to 0) ml/min/1.73m², P =0.085. Early eGFR decrease with spironolactone was positively correlated with BNP (β =1.1 per Log₂ decrease), KIM-1 (β =2.3 per Log₂ decrease), and SBP (β =1.2 per 10 mmHg decrease), and negatively correlated with Renin (β =-2.5 per Log₂ increase); all P <0.01.

Legend: eGFR, estimated glomerular filtration rate; M0, month 0/baseline; M1, month 1; M9, month 9; BNP, brain natriuretic peptide; KIM-1, kidney injury molecule-1; SBP, systolic blood pressure.

Graphical abstract. Spironolactone induces an early hemodynamic eGFR decrease

HOMAGE: spironolactone vs usual care in people at risk of developing HF



Legend: eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; KIM-1, kidney injury molecule-1; SBP, systolic blood pressure.